Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Rite Aid Gains After Analyst Says It May Be Walgreen Target

Don't Miss Out —
Follow us on:
Rite Aid Gains
A Rite Aid drugstore in Camp Hill, Pennsylvania. Photographer: Bradley C. Bower/Bloomberg

Nov. 28 (Bloomberg) -- Rite Aid Corp. climbed 7.3 percent after Susquehanna Financial Group said it may be a takeover target of Walgreen Co., the largest U.S. drugstore chain.

Acquiring Rite Aid, the third-largest U.S. drugstore chain, for $1.60 a share in stock would boost Walgreen’s profit by about 5.8 percent in the first year after the transaction, Joseph Stauff, an analyst with Susquehanna in New York, wrote today in a note to clients.

Growing “hostility” over reimbursement rates between drugstore chains and companies that manage drug benefits for corporations and other employers may lead to consolidation among retailers, Stauff said. Walgreen, which controls almost 28 percent of prescription sales, would capture another 7.1 percent with Rite Aid, he estimated.

CVS Caremark Corp.’s market share is 23.5 percent, according to Susquehanna.

Rite Aid advanced to $1.18 at 4 p.m. in New York. Walgreen rose 1 percent to $32.79.

Walgreen, based in Deerfield, Illinois, doesn’t comment on speculation, spokesman Jim Cohn said in an e-mail. Susan Henderson, a spokesman for Camp Hill, Pennsylvania-based Rite Aid, also declined comment.

Walgreen’s contract to provide prescriptions for customers of Express Scripts Inc., a pharmacy benefit manager, expires at the end of the year. The two companies haven’t resolved differences over how much Walgreen would charge for prescriptions and how much Express Scripts would reimburse the retailer, executives told analysts at Lazard Capital Markets conference Nov. 16.

To contact the reporter on this story: Chris Burritt in Greensboro at cburritt@bloomberg.net

To contact the editor responsible for this story: Robin Ajello at rajello@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.